Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus resminostat vs S-1 plus placebo in platinum-gemcitabine refractory biliary tract cancer
jRCT2080223827Phase 2Completed
- Sponsor
- Yakult Honsha
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 2 more comparing Resminostat + S-1 with Placebo + S-1 (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2018; status: completed.
02
Drugs
Resminostat
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on jRCT2080223827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223827.